Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00351273 · ClinicalTrials.gov registry record · Phase 3

Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria

A Phase 3 study, sponsored by University of South Florida.

Completed
Registry status
Phase 3
Development phase
42
Enrollment target

NCT00351273 is a Phase 3 study that has completed, run by University of South Florida. The registered enrollment target is 42 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00351273, a Phase 3 study, has completed, sponsored by University of South Florida.

COMPLETED
Registry status
Phase 3
Development phase
42 participants
Enrollment target

Study Summary

Reactive arthritis, also known as Reiter's syndrome, is a form of arthritis that occurs as a reaction to an infection elsewhere in the body. It is characterized by inflammation of the joints, tendons, urogenital tract, and eyes. Pain and swelling in the knees, ankles, and feet are common. This study will determine the effectiveness of antibiotic therapy in treating people with chlamydia-induced reactive arthritis that has lasted for more than 6 months.

Interventions

  • DRUG Placebo
  • DRUG Doxycycline and Rifampin
  • DRUG Azithromycin and Rifampin

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2006-05
Est. Completion 2008-09
Phase Phase 3

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT00351273

The ClinicalTrials.gov registry entry for NCT00351273 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00351273 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00351273 about?

NCT00351273 is a clinical study titled "Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria". Reactive arthritis, also known as Reiter's syndrome, is a form of arthritis that occurs as a reaction to an infection elsewhere in the body. It is characterized by inflammation of the joints, tendons, urogenital tract, and eyes. Pain and swelling in the knees, ankles, and feet are common. This study...

What is the current status of trial NCT00351273?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2006-05. Estimated completion is 2008-09.

What interventions are being tested in trial NCT00351273?

The interventions under investigation include: Placebo (DRUG), Doxycycline and Rifampin (DRUG), Azithromycin and Rifampin (DRUG).

Who is sponsoring clinical trial NCT00351273?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.